Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 1 2

Status

Completed 5

Sponsor Class

INDUSTRY 5

Study Type

Interventional 5

Sponsor

Cancer Type

Dermatologic 5Other neoplasm 1

Conditions

Keratosis, Actinic 4Skin Diseases 1Precancerous Conditions 1Keratosis 1Carcinoma, Basal Cell 1

Interventions

Cyclophosphamide 909Carboplatin 787pembrolizumab 744Paclitaxel 742Cisplatin 709Bevacizumab 706Gemcitabine 619Docetaxel 579Rituximab 548Radiotherapy 541Dexamethasone 511Nivolumab 488Doxorubicin 444Fluorouracil 392Capecitabine 376Etoposide 358Pemetrexed 337Cytarabine 335Oxaliplatin 333Lenalidomide 328Prednisone 326fludarabine phosphate 316Erlotinib Hydrochloride 314Trastuzumab 300Leucovorin 299fludarabine 296Vincristine 287Filgrastim 284Bortezomib 284Cetuximab 276

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Interventional × Has results × BF-200 ALA × Clear all
NCT05060237 2024-10-17

Study to Evaluate Safety and Tolerability of BF-200 ALA (AmeluzĀ®) for Photodynamic Therapy in the Treatment of the Expanded Field of Actinic Keratosis on Face and Scalp

Biofrontera Bioscience GmbH

Phase 1 Completed
112 enrolled 21 charts
DermatologicOther neoplasm

Keratosis, Precancerous Conditions, Skin Diseases, Keratosis, Actinic

NCT02144077 2022-11-03

Safety and Efficacy Study for the Treatment of Non-Aggressive Basal Cell Carcinoma With Photodynamic Therapy

Biofrontera Bioscience GmbH

Phase 3 Completed
281 enrolled 16 charts
Dermatologic

Carcinoma, Basal Cell

NCT04319159 2021-11-11

Study to Evaluate the Safety of BF-200 ALA (AmeluzĀ®) for Photodynamic Therapy (PDT) in the Treatment of Expanded Fields of Actinic Keratosis (AK)

Biofrontera Bioscience GmbH

Phase 1 Completed
48 enrolled 27 charts
Dermatologic

Keratosis, Actinic

NCT02799069 2017-04-28

Evaluation of Safety and Efficacy of BF-200 ALA for the Treatment of Actinic Keratosis With Photodynamic Therapy

Biofrontera Bioscience GmbH

Phase 3 Completed
571 enrolled 46 charts
Dermatologic

Keratosis, Actinic

NCT02799082 2017-04-06

Evaluation of Efficacy and Safety of BF-200 ALA Used With Photodynamic Therapy in Patients With Actinic Keratosis.

Biofrontera Bioscience GmbH

Phase 3 Completed
122 enrolled 24 charts
Dermatologic

Keratosis, Actinic

Data powered by HemOnc (CC BY 4.0) Colophon ⚔